Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vistagen Therapeutics Inc    VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 06:38pm EDT

Item 7.01 Regulation FD Disclosure.

On January 7, 2019, VistaGen Therapeutics, Inc. (the "Company") began utilizing a new corporate presentation. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

In addition, this Current Report on Form 8-K and the exhibit(s) attached hereto may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties.

Item 9.01 Exhibits.

See Exhibit Index.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VISTAGEN THERAPEUTICS INC
03/14VISTAGEN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events (form 8-K)
AQ
03/04VISTAGEN THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financ..
AQ
02/26VistaGen Therapeutics Announces Pricing of Underwritten Public Offering of Co..
GL
02/26VISTAGEN THERAPEUTICS : Announces Proposed Public Offering of Common Stock
AQ
02/25VISTAGEN THERAPEUTICS : Announces Proposed Public Offering of Common Stock
AQ
02/19VISTAGEN THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
02/19VISTAGEN THERAPEUTICS : Receives AV-101 Japanese Patent for Treatment of Depress..
AQ
02/13VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatm..
GL
02/12VISTAGEN THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
02/12VistaGen Therapeutics Reports Fiscal 2019 Third Quarter Financial Results
GL
More news
Financials ($)
Sales 2019 -
EBIT 2019 -19,2 M
Net income 2019 -19,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 0
Capi. / Sales 2020 0
Capitalization 48,5 M
Chart VISTAGEN THERAPEUTICS INC
Duration : Period :
Vistagen Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VISTAGEN THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,00 $
Spread / Average Target 408%
EPS Revisions
Managers
NameTitle
Shawn K. Singh Chief Executive Officer & Director
H. Ralph Snodgrass President, Director & Chief Scientific Officer
Jon Sheldon Saxe Chairman
Jerrold D. Dotson Chief Financial Officer, Secretary & VP
Mark A. Smith Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VISTAGEN THERAPEUTICS INC-21.33%49
CSL LIMITED5.48%63 534
BIOGEN-26.80%42 629
ALEXION PHARMACEUTICALS35.88%29 098
SAMSUNG BIOLOGICS CO LTD--.--%19 732
GRIFOLS2.45%16 228